Semaglutide, marketed as Wegovy, proved effective against obesity in children ages 6 to 12 in a clinical trial. Nearly 80% of children receiving the drug improved their weight status. The findings could pave the way for authorization in this age group, while leaving important questions of prescribing caution for patients who are still growing.
The trial, published in the New England Journal of Medicine, had been awaited by specialists in childhood obesity. “We lacked reassuring data to offer the drug to this population, which by definition is still growing,” said Professor Béatrice Dubern, a physician in the pediatric nutrition and gastroenterology department at Trousseau Hospital in Paris. Experts remain cautious about prescribing the treatment to children.
Increasingly used in adults, semaglutide belongs to a family of drugs called GLP-1 analogs. They mimic a natural hormone produced by the digestive tract that signals fullness to the brain. Their effect disappears when treatment stops: effectiveness while taking the medication does not mean the benefit persists after it is discontinued.
Another drug in this family, liraglutide, marketed as Saxenda, was already authorized in Europe in 2025 for children under 12. But it is rarely prescribed because it is not reimbursed. For these young patients, a drug’s authorization and practical access to it remain two separate steps.


